cell-penetrating peptide targeting SUMO2-K11 lactylation

A **cell-penetrating peptide targeting SUMO2-K11 lactylation** is a designed peptide-based therapeutic agent intended to modulate the lactylation of lysine 11 on Small Ubiquitin-like Modifier 2 (SUMO2) proteins. Cell-penetrating peptides (CPPs) are short amino acid sequences capable of efficiently crossing cellular membranes and delivering cargoes to intracellular targets[3][5]. Lactylation is a novel post-translational modification (PTM) of lysine residues, derived from lactate, that plays important roles in epigenetic regulation and tumor drug resistance, affecting transcriptional reprogramming and protein-protein interactions[4][6]. SUMO2-K11 lactylation would refer to the addition of a lactyl group to the K11 lysine of SUMO2, potentially influencing SUMO chain topology and downstream signaling[2]. Therapeutic targeting of lactylation might reduce drug resistance mechanisms in cancer and other diseases[6]. The peptide is intended to penetrate cells and selectively interact with SUMO2 modified at K11 by lactylation, either inhibiting, reversing, or exploiting this modification for therapeutic benefit. This agent is experimental and likely in preclinical development or basic research; there is no known approved or established product fitting this exact description.